139 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
balance
Ambition of 50% of women in senior leadership roles by 2025
Ambition of 40% of women in executive roles by 2025
Engagement with communities
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
In and beyond the workplace
Global Gender balance
Ambition of 50% of women in senior leadership roles by 2025
Ambition of 40% of women in executive
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
and
marketed products)
In and beyond the workplace
Gender balance
Ambition of 50% of women in senior leaders by 2025
Ambition of 40% of women
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
electricity by 2025 for all manufacturing operations globally
Reached 41% representation of women in senior leadership roles as part of goal to reach 50 …
Q2 2023
Diverse Senior Leadership
% of women
37.5% of our executives
42.1% of our senior leaders were women
38.0% of our executives
42.4% of our
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
and the Scientific Committee. The Board of Directors has 16 members, of whom six are women and two are directors representing employees. The Board of Directors … 2020 as part of the goal to achieve 100% renewable electricity by 2025 for all manufacturing operations globally ;
Reached 41% representation of women
6-K
EX-99.1
xna873
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.1
t3b7q7ecm79a1xe u5
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.2
lgarxr
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
wc59 sfm9ju85jhb6s9v
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
r3rq nanyif
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
kgy8p dt2mpd
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
2hy 7s9mbe9b
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
8hyb1lghstrqec9
31 May 22
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
10:56am
6-K
EX-99.1
qmi135kv
9 May 22
Approval of the financial statements for the fiscal year 2021
2:29pm
6-K
EX-99.1
bleedz1bsr 5fym
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
p95o1yy phi4uwy
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
006 h0ie3x83
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
6-K
EX-99.1
5m3ftv6h
6 Dec 21
Current report (foreign)
2:45pm